These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38244208)

  • 21. Therapy-related acute myeloid leukaemia and myelodysplastic syndrome in Victoria, Australia 2003-2014.
    Ong DM; Farrugia H; Wei A
    Intern Med J; 2018 Jul; 48(7):822-829. PubMed ID: 29236346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary Acute Leukemia in Sarcoma Patients: A Population-Based Study.
    Sanford NN; Martin AM; Brunner AM; Cote GM; Choy E; DeLaney TF; Aizer AA; Chen YL
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):687-694. PubMed ID: 29413281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML.
    Lalayanni C; Gavriilaki E; Athanasiadou A; Iskas M; Papathanasiou M; Marvaki A; Mpesikli S; Papaioannou G; Mallouri D; Batsis I; Papalexandri A; Sakellari I; Anagnostopoulos A
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):e233-e240. PubMed ID: 34756570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.
    Keegan THM; Bleyer A; Rosenberg AS; Li Q; Goldfarb M
    JAMA Oncol; 2017 Nov; 3(11):1554-1557. PubMed ID: 28426850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
    De Witte T; Muus P; De Pauw B; Haanen C
    Cancer; 1990 Sep; 66(5):831-7. PubMed ID: 2386911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment responses, outcomes, and prognostic factors associated with them in patients with secondary acute myeloid leukemia].
    Ma L; Zhao T; Chen YY; Jiang H; Xu LP; Zhang XH; Wang Y; Sun YQ; Mo XD; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):124-131. PubMed ID: 36948866
    [No Abstract]   [Full Text] [Related]  

  • 27. Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population-based study.
    Mo X; Zhou M; Yan H; Chen X; Wang Y
    Cancer Med; 2021 Aug; 10(15):5338-5346. PubMed ID: 34189859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex disparity in childhood and young adult acute myeloid leukemia (AML) survival: Evidence from US population data.
    Hossain MJ; Xie L
    Cancer Epidemiol; 2015 Dec; 39(6):892-900. PubMed ID: 26520618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival differences in childhood and young adult acute myeloid leukemia: A cross-national study using US and England data.
    Xie S; Hossain MJ
    Cancer Epidemiol; 2018 Jun; 54():19-24. PubMed ID: 29554538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
    Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
    Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
    Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
    Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes.
    Yu S; Fan Z; Ma L; Wang Y; Huang F; Zhang Q; Huang J; Wang S; Xu N; Xuan L; Xiong M; Han L; Sun Z; Zhang H; Liu H; Yu G; Shi P; Xu J; Wu M; Guo Z; Xiong Y; Duan C; Sun J; Liu Q; Zhang Y
    JAMA Netw Open; 2021 Jul; 4(7):e2115991. PubMed ID: 34232303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
    Rosenstock AS; Niu J; Giordano SH; Zhao H; Wolff AC; Chavez-MacGregor M
    Cancer; 2018 Mar; 124(5):899-906. PubMed ID: 29236294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
    Meyers J; Yu Y; Kaye JA; Davis KL
    Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
    Kaplan HG; Malmgren JA; Li CI; Calip GS
    Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival disparities by age and country of diagnosis for patients with acute leukemia.
    Redaniel MT; Pulte D; Jeffreys M
    Leuk Lymphoma; 2015; 56(10):2787-92. PubMed ID: 25669926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of poverty and race on outcomes in acute myeloid leukemia.
    Byrne MM; Halman LJ; Koniaris LG; Cassileth PA; Rosenblatt JD; Cheung MC
    Am J Clin Oncol; 2011 Jun; 34(3):297-304. PubMed ID: 20562587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.
    Talati C; Goldberg AD; Przespolewski A; Chan O; Ali NA; Kim J; Famulare C; Sallman D; Padron E; Kuykendall A; Lancet JE; Wang E; Tallman MS; Komrokji R; Sweet K
    Leuk Res; 2020 Jun; 93():106367. PubMed ID: 32408060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization and prognostic features of secondary acute myeloid leukemia in survivors of multiple myeloma.
    Jia J; Chen W
    Am J Cancer Res; 2023; 13(10):4803-4810. PubMed ID: 37970345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age and genetics: how do prognostic factors at diagnosis explain disparities in acute myeloid leukemia?
    Patel MI; Ma Y; Mitchell BS; Rhoads KF
    Am J Clin Oncol; 2015 Apr; 38(2):159-64. PubMed ID: 23608826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.